盐酸羟考酮注射液联合右美托咪定对肝癌射频消融术患者MAP、HR及SpO2的影响(1)
[摘要] 目的 探討盐酸羟考酮注射液联合右美托咪定对肝癌射频消融术患者MAP、HR及SpO2的影响。 方法 选取我院2014年5月～2016年5月收治的肝癌患者80例，依据随机数字表法将患者分为盐酸羟考酮注射液联合右美托咪定组(联合应用组，n=40)和单纯右美托咪定组(单独应用组，n=40)，对两组患者的MAP、HR、SpO2、Ramsay评分、VAS评分及并发症发生情况进行统计分析。 结果 T1、T2、T3、T4时联合应用组患者的MAP、HR均显著低于单独应用组(P<0.05)；T2、T3时联合应用组的Ramsay评分均显著高于单独应用组(P<0.05)；不同时点两组SpO2差异不显著。术后1 h、2 h、3 h联合应用组患者的VAS评分均显著低于单独应用组(P<0.05)；联合应用组患者的并发症发生率5.0%(2/40)显著低于单独应用组45.0%(18/40)(P<0.05)。 结论 盐酸羟考酮注射液联合右美托咪定较单独右美托咪定更能有效降低肝癌射频消融术患者的MAP、HR，且不会对SpO2造成较大程度的影响。
[关键词] 盐酸羟考酮注射液；右美托咪定；肝癌；射频消融术；平均动脉压；心率；血氧饱和度
[中图分类号] R614；R735.7 [文献标识码] B [文章编号] 1673-9701(2016)35-0106-04
Effects of oxycodone hydrochloride injection combined with dexmedetomidine on MAP， HR and SpO2 in the patients with hepatocellular carcinoma undergoing radiofrequency ablation
SHEN Yajian FANG Jun XIE Kangjie
Department of Anesthesiology， Zhejiang Cancer Hospital， Hangzhou 310022， China
[Abstract] Objective To investigate the effect of oxycodone hydrochloride injection combined with dexmedetomidine on MAP， HR and SpO2 in the patients with hepatocellular carcinoma undergoing radiofrequency ablation. Methods A total of 80 patients with hepatocellular carcinoma who were admitted to our hospital from May 2014 to May 2016 were selected. The patients were divided into two groups according to the method of random number table： oxycodone hydrochloride injection combined with dexmedetomidine group(combined application group， n=40) and single dexmedetomidine group(single application group， n=40). The MAP， HR， SpO2， Ramsay score， VAS score and the incidence of complications were statistically analyzed in both groups. Results The MAP and HR of the patients in the combined application group at T1， T2， T3 and T4 were significantly lower than those in the single application group(P<0.05)； the Ramsay scores in the combined application group at T2 and T3 were significantly higher than those in the single application group(P<0.05)； there was no significant difference in SpO2 between two groups at different time points. The VAS scores in the patients in the combined application group 1 h， 2 h and 3 h after the surgery were significantly lower than those in the single application group(P<0.05)； the incidence rate of complications was 5.0%(2/40) in the combined application group， significantly lower than that of 45.0%(18/40) in the single application group(P<0.05). Conclusion Oxycodone hydrochloride injection combined with dexmedetomidine is more effective than single dexmedetomidine in reducing the MAP and HR of the patients with hepatocellular carcinoma undergoing radiofrequency ablation， and does not have the effect on SpO2 to a great extent. (沈亚建 方军 解康杰)
[关键词] 盐酸羟考酮注射液；右美托咪定；肝癌；射频消融术；平均动脉压；心率；血氧饱和度
[中图分类号] R614；R735.7 [文献标识码] B [文章编号] 1673-9701(2016)35-0106-04
Effects of oxycodone hydrochloride injection combined with dexmedetomidine on MAP， HR and SpO2 in the patients with hepatocellular carcinoma undergoing radiofrequency ablation
SHEN Yajian FANG Jun XIE Kangjie
Department of Anesthesiology， Zhejiang Cancer Hospital， Hangzhou 310022， China
[Abstract] Objective To investigate the effect of oxycodone hydrochloride injection combined with dexmedetomidine on MAP， HR and SpO2 in the patients with hepatocellular carcinoma undergoing radiofrequency ablation. Methods A total of 80 patients with hepatocellular carcinoma who were admitted to our hospital from May 2014 to May 2016 were selected. The patients were divided into two groups according to the method of random number table： oxycodone hydrochloride injection combined with dexmedetomidine group(combined application group， n=40) and single dexmedetomidine group(single application group， n=40). The MAP， HR， SpO2， Ramsay score， VAS score and the incidence of complications were statistically analyzed in both groups. Results The MAP and HR of the patients in the combined application group at T1， T2， T3 and T4 were significantly lower than those in the single application group(P<0.05)； the Ramsay scores in the combined application group at T2 and T3 were significantly higher than those in the single application group(P<0.05)； there was no significant difference in SpO2 between two groups at different time points. The VAS scores in the patients in the combined application group 1 h， 2 h and 3 h after the surgery were significantly lower than those in the single application group(P<0.05)； the incidence rate of complications was 5.0%(2/40) in the combined application group， significantly lower than that of 45.0%(18/40) in the single application group(P<0.05). Conclusion Oxycodone hydrochloride injection combined with dexmedetomidine is more effective than single dexmedetomidine in reducing the MAP and HR of the patients with hepatocellular carcinoma undergoing radiofrequency ablation， and does not have the effect on SpO2 to a great extent. (沈亚建 方军 解康杰)